<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rizzo, Toni</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Aebi, Stefan</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer: The CALOR Trial</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-02-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">14-15</style></pages><abstract><style  face="normal" font="default" size="100%">Patients who develop isolated local or regional recurrences (ILRR) of breast cancer have a high risk of distant metastasis and death. The Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer (Chemotherapy as Adjuvant for Locally Recurrent Breast Cancer) [CALOR; NCT00074152] trial investigated the impact of chemotherapy on disease-free survival and overall survival in patients with ILRR.</style></abstract><number><style face="normal" font="default" size="100%">20</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>